Shenghao Shi
Managing Partner @ RiverHead Capital
Shenghao Shi is a Series B investor at RiverHead Capital focused on Biotechnology and Health Care. Mr. Shenghao Shi is the Managing Partner of Sunshine Riverhead Capital.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Shenghao Shi invests in
Stages Shenghao Shi invests in
Countries Shenghao Shi invests in
Investment Focus
Industry
- Biotechnology 4 (67%)
- Health Care 3 (50%)
- Medical 2 (33%)
- Medical Device 2 (33%)
- Hospital 1 (17%)
Stage
- Series B 3 (50%)
- Series D 1 (17%)
- Venture - Series Unknown 1 (17%)
Country
- China 4 (67%)
- United States 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nanos Medical
|
Nanos Medical is engaged in the research and development, manufacturing and sales of disposable medical devices. The company's current core products are concentrated in the cardiovascular and ENT fields. | $41.2M / Venture - Series Unknown / Feb 14, 2025 | |
Medical Source
|
Yiyuan Medical Technology is a high-tech enterprise specializing in the research and development, production, sales, technical services and technical consultation of medical CT tubes. | $13.9M / Series B / Aug 04, 2023 | |
Yingsheng Biology
|
Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product lineincludes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level. | Series B / Nov 12, 2020 | |
|
Yingsheng Biology
|
Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product lineincludes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level. | Series B / Nov 12, 2020 | |
Sirnaomics
|
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology. | $105M / Series D / Oct 23, 2020 | |
Lepu Bio
|
Lepu Bio is a biotech company that develops a tumor immunology technology. It has established an industrial platform for target discovery, drug discovery, development, and production. The company's core products, PD-1, PD-L1, oncolytic virus, and multiple ADC products, have entered the clinical stage I-III. | $185.7M / Series B / Aug 06, 2020 |
Co-Investors
About RiverHead Capital
River Head Capital is the private equity arm of the Sunshine Insurance Group.River Head Capital was established in January 2015. It is the first batch of insurance private fund pilot units approved by the China Insurance Regulatory Commission. The fund management scale has reached 17 billion yuan.Adhering to the corporate vision of “making lifebetter”, with the mission of “creating value, trustworthiness, investing resources in the most valuable companies, and gaining the trust of investors with excellent returns”, the company will actively deploy medical health and emerging Industries, emerging consumption, industrial mergers and acquisitions, real estate and other fields, through entrepreneurial support, strategic investment, financial investment, mergers and acquisitions, corporate restructuring, cross-border investment and other diversified ways to invest in enterprises, comprehensively enhance corporate value and support the healthy and sustainable development of enterprises. At present, River Head Capital has invested in a number of companies in the fields of medical, pharmaceutical, Internet, and innovative financial services.
RiverHead Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Shenghao Shi
Managing Partner
|
|||
|
Wenwen Zhang
CEO
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Shenghao Shi invest in?
Shenghao Shi invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series D stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Shenghao Shi last invest?
The most recent investment recorded for Shenghao Shi closed in Feb 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
